Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Status:
Completed
Trial end date:
2019-11-18
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab,
alone and in combination with other anti-cancer therapies in patients with advanced
malignancies.